Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD
- 8 March 2023
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 377, 578066
Abstract
No abstract availableKeywords
Funding Information
- Rehabilitation Research and Development Service
- University Hospitals of Cleveland
- U.S. Department of Veterans Affairs
This publication has 11 references indexed in Scilit:
- Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum DisordersNeurology Neuroimmunology & Neuroinflammation, 2022
- Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort StudyCNS Drugs, 2021
- The prevalence of MS in the United StatesNeurology, 2019
- Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disordersNeurology Neuroimmunology & Neuroinflammation, 2018
- Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center studySeminars in Arthritis and Rheumatism, 2018
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammationJournal of Neurology, 2018
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisNew England Journal of Medicine, 2017
- Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple SclerosisNeurology Research International, 2011
- The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and NeurodegenerationNeuron, 2006